{"entity":{"id":"card11","kind":"target","name":"CARD11","aka":["caspase recruitment domain family member 11","Caspase recruitment domain-containing protein 11","CARMA1","BIMP3"],"tldr":"CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.","summary":"Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement. Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways. Upon activation in response to TCR or BCR triggering, CARD11 homooligomerises to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.84, animal model 0.54, genetic association 0.00, somatic mutation 0.87). IntOGen calls it a driver in 11 cohorts (9 activating, 2 loss-of-function), covering Burkitt Lymphoma, Colorectal Adenocarcinoma, Diffuse Large B-Cell Lymphoma, NOS, Hepatocellular Carcinoma, Malignant Lymphoma, Non-Hodgkin Lymphoma and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:16393","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16393"},{"label":"UniProt Q9BXL7","url":"https://www.uniprot.org/uniprotkb/Q9BXL7/entry"},{"label":"NCBI Gene 84433","url":"https://www.ncbi.nlm.nih.gov/gene/84433"},{"label":"Ensembl ENSG00000198286","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198286"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","hcc","skin-cancer","colorectal","ovarian","leukaemia","lung-cancer","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["bcr-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 9 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CARD11","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:16393","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16393","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9BXL7","url":"https://www.uniprot.org/uniprotkb/Q9BXL7/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CARD11","url":"https://civicdb.org/features/16180","note":"2 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000198286","url":"https://platform.opentargets.org/target/ENSG00000198286/associations","note":"association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: colorectal cancer 0.55, gastric cancer 0.51, melanoma 0.54, diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.70, skin cancer 0.58 (GraphQL API, CC0)"},{"label":"IntOGen CARD11","url":"https://www.intogen.org/search?gene=CARD11","note":"driver in 11 cohorts (Act 9, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:16393","ensembl":"ENSG00000198286","uniprot":"Q9BXL7","entrez":"84433","biology":"Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement. Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways. Upon activation in response to TCR or BCR triggering, CARD11 homooligomerises to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Promotes linear ubiquitination of BCL10 by promoting the targeting of BCL10 to RNF31/HOIP. Stimulates the phosphorylation of BCL10. Location: Cytoplasm; Membrane raft (UniProt). Locus 7p22.2 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.70 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)","Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)","Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)","Ovarian cancer: IntOGen driver in 1 cohort (OVT)","Leukaemia: Open Targets association 0.53 with leukaemia (MONDO_0005059)"],"targetClass":"oncogene","prevalence":[]},"route":"/targets/card11/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"pathway":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/"}]}}